Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds TD Securities Downgrades Mullen Group to Hold

TD Securities Downgrades Mullen Group to Hold

TD Securities analyst Tim James downgrades Mullen Group (TSX:MTL) from Buy to Hold.

byBenzinga Newsdesk

December 21, 2022

1 minute read

TD Securities analyst Tim James downgrades Mullen Group (TSX:MTL) from Buy to Hold.

From Earlier: WSJ Reporter Says ‘The October inflation report is likely to keep the Fed on track to approve a 50-basis-point interest-rate increase next month’

By Benzinga Newsdesk

November 10, 1:18 PM

https://twitter.com/NickTimiraos/status/1590704981552005120

SPY

Dada Nexus Posts Q2 Bottomline Above Street View

By Shivani Kumaresan

August 16, 5:44 AM

Dada Nexus Ltd (NASDAQ: DADA) reported

DADA

Willis Towers Watson Q4 Adj EPS $6.33 Beats $6.22 Estimate, Sales $2.72B Beat $2.69B Estimate

By Benzinga Newsdesk

February 9, 7:01 AM

Willis Towers Watson (NASDAQ:WTW) reported quarterly adjusted earnings of $6.33 per share which beat the analyst consensus estimate of $6.22 by 1.77 percent. This is a 11.64 percent increase over earnings of $5.67 per

WTW

Reported Late Wednesday, Iveric Bio Announces Pricing Of $300M Public Offering Of 13,350,000 Shares Of Common Stock At A Price Of $22.50/Share

By Benzinga Newsdesk

December 1, 2:12 AM

IVERIC bio, Inc. (NASDAQ:ISEE) (the "Company"), today announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and commissions.

ISEE

TD Securities Downgrades Mullen Group to Hold

Related Posts

From Earlier: WSJ Reporter Says ‘The October inflation report is likely to keep the Fed on track to approve a 50-basis-point interest-rate increase next month’

Dada Nexus Posts Q2 Bottomline Above Street View

Willis Towers Watson Q4 Adj EPS $6.33 Beats $6.22 Estimate, Sales $2.72B Beat $2.69B Estimate

Reported Late Wednesday, Iveric Bio Announces Pricing Of $300M Public Offering Of 13,350,000 Shares Of Common Stock At A Price Of $22.50/Share